Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Functional Role of Microrna 15a/16-1 as Tumor Suppressor Genes in Multiple Myeloma.

Moshe E Gatt, MD, Margaret Ebert, Mala Mani, PhD, Yunyu Zhang, Roi Gazit, PhD, Daniel E Carrasco, Jui Dutta, Sophia Adamia, Nikhil C. Munshi, Stéphane Minvielle, Herve Avet-Loiseau, MD, PhD, Yu-Tzu Tai, Ph.D., Kenneth C. Anderson, MD, Daniel Ruben Carrasco, M.D., Ph.D.

Blood (2009) 114 (22): 1963.

https://doi.org/10.1182/blood.V114.22.1963.1963

Published: 2009

Journal Articles

DAPK2 and PIM1 Are Myeloma-Associated Antigens That Elicit Coordinated B and T Cell Immunity After Syngeneic HSCT.

Melinda Biernacki, MD, Anselmo Alonso, Guanglan Zhang, Li Zhang, PhD, Wandi Zhang, Yu-Tzu Tai, Ph.D., Nikhil Munshi, Edwin P Alyea, III, MD, Robert J Soiffer, MD, Vladimir Brusic, Ph.D., Jerome Ritz, MD, Kenneth C. Anderson, MD, Catherine J Wu, MD

Blood (2009) 114 (22): 2445.

https://doi.org/10.1182/blood.V114.22.2445.2445

Published: 2009

Journal Articles

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Yu-Tzu Tai, Ph.D., Michel de Weers, Ph.D., Xian-Feng Li, MS, Weihua Song, MD, Sabikun Nahar, B.S., Joost M Bakker, Tom Vink, Daniëlle Jacobs, Lukas Oomen, Wim K Bleeker, Nikhil C. Munshi, MD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 608.

https://doi.org/10.1182/blood.V114.22.608.608

Published: 2009

Journal Articles

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Umesh Muchhal, Ph.D., Xian-Feng Li, MS, Sabikun Nahar, B.S., Weihua Song, MD, Holly Horton, Ph.D, Hanh Nguyen, Sher Karki, John Desjarlais, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 609.

https://doi.org/10.1182/blood.V114.22.609.609

Published: 2009

Journal Articles

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

Yu-Tzu Tai, Ph.D., Kihyun Kim, M.D., Xian-Feng Li, M.S., Mariateresa Fulciniti, Ph.D., Weihua Song, M.D., Sabikun Nahar, B.S., Peter Burger, B.S., Mathew J. Rumizen, Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D, Teru Hideshima, M.D., Ph.D., Robert L Schlossman, M.D., Ph.D., Nikhil C. Munshi, Paul Richardson, M.D., Ph.D., Ann Clark, Ph.D., Janet Ogden, Ph.D., Goutopoulos Andreas, Ph.D., Luca Rastelli, Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3848.

https://doi.org/10.1182/blood.V114.22.3848.3848

Published: 2009

Journal Articles

HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells.

Weihua Song, MD, Yu-Tzu Tai, Ph.D., Ze Tian, Ph.D, Teru Hideshima, M.D., Ph.D., Dharminder Chauhan, Ph.D, Puru Nanjappa, MS, Mark A. Exley, Ph.D, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2009) 114 (22): 1646.

https://doi.org/10.1182/blood.V114.22.1646.1646

Published: 2009

Journal Articles

BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.

Hiroshi Yasui, MD, PhD, Teru Hideshima, M.D., Ph.D., Hiroshi Ikeda, M.D., Ph.D., Janice Jin, M.D., Enrique M. Ocio, D., Ph.D., Tanyel Kiziltepe, Ph.D, Yutaka Okawa, M.D., Ph.D., Sonia Vallet, M.D., Ph.D., Shweta Chhetri, Kenji Ishitsuka, M.D., Ph.D., Yu-Tzu Tai, Ph.D., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Chris Pargellis, Ph.D., Neil Moss, Ph.D., Noopur Raje, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3440.

https://doi.org/10.1182/blood.V108.11.3440.3440

Published: 2006

Journal Articles

Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.

Dharminder Chauhan, PhD, Laurence Catley, M.D, Mugdha Velankar, M.S, Anthony Letai, M.D, Teru Hideshima, Ph.D, Klaus Podar, M.D, Hiroshi Yasui, M.D, Nicholas Mitsiades, M.D, Constantine Mitsiades, M.D, Yu-Tzu Tai, Ph.D, Noopur Raje, M.D, Nikhil Munshi, M.D, Michael A. Palladino, Ph.D, Kenneth C. Anderson, M.D

Blood (2005) 106 (11): 3378.

https://doi.org/10.1182/blood.V106.11.3378.3378

Published: 2005

Journal Articles

Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.

Dharminder Chauhan, Ph.D, Guilan Li, M.S, Klaus Podar, Ph.D, Teru Hideshima, Ph.D, Kenji Ishitsuka, M.D, Laurence Catley, M.D, Martin Sattler, Ph.D, Yu-Tzu Tai, Ph.D, Renate Burger, Ph.D, Paul Richardson, M.D, Yan Chang, Ph.D, Joanne Schindler, M.D, Bradley Carver, M.D, Kenneth C. Anderson, M.D

Blood (2004) 104 (11): 2456.

https://doi.org/10.1182/blood.V104.11.2456.2456

Published: 2004

Journal Articles

A Fully Human Antagonist Anti-CD40 Antibody Triggers Significant Antitumor Activity Against Human Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Xian-Feng Li, M.S., Xia Tong2, M.S., Laurence Catley, M.D., Daniel Santos, M.D., Olivier Tournilhac, M.D., Ph.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Mohammad Luqman2, Ph.D., Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 2414.

https://doi.org/10.1182/blood.V104.11.2414.2414

Published: 2004

Journal Articles

Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Laurence Catley, M.D., Xian-Feng Li, M.S., Makoto Hamasaki, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Teru Hideshima, M.D., Ph.D., Dharminder Chauhan, Ph.D., Robert Schlossman, M.D., Paul Richardson, M.D., Steven P. Streon, M.D., Ph.D., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 1498.

https://doi.org/10.1182/blood.V104.11.1498.1498

Published: 2004

NARROW

The Functional Role of Microrna 15a/16-1 as Tumor Suppressor Genes in Multiple Myeloma.

DAPK2 and PIM1 Are Myeloma-Associated Antigens That Elicit Coordinated B and T Cell Immunity After Syngeneic HSCT.

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells.

BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.

Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.

Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.

A Fully Human Antagonist Anti-CD40 Antibody Triggers Significant Antitumor Activity Against Human Multiple Myeloma.

Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only